J Urol. 2021 Jan;205(1):14-21. doi: 10.1097/JU.0000000000001375. Epub 2020 Sep 22.
The summary presented herein represents Part I of the two-part series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline discussing prognostic and treatment recommendations for patients with biochemical recurrence without metastatic disease after exhaustion of local treatment options as well as those with metastatic hormone-sensitive prostate cancer. Please refer to Part II for discussion of the management of castration-resistant disease.
The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. A research librarian conducted searches in Ovid MEDLINE (1998 to January Week 5 2019), Cochrane Central Register of Controlled Trials (through December 2018), and Cochrane Database of Systematic Reviews (2005 through February 6, 2019). An updated search was conducted prior to publication through January 20, 2020. The methodology team supplemented searches of electronic databases with the studies included in the prior AUA review and by reviewing reference lists of relevant articles.
The Advanced Prostate Cancer Panel created evidence- and consensus-based guideline statements to aid clinicians in the management of patients with advanced prostate cancer. Such statements are summarized in figure 1[Figure: see text] and detailed herein.
This guideline attempts to improve a clinician's ability to treat patients diagnosed with advanced prostate cancer. Continued research and publication of high-quality evidence from future trials will be essential to improve the level of care for these patients.
本文概述了两部分系列中的第一部分，该系列专门讨论了高级前列腺癌：AUA/ASTRO/SUO 指南，讨论了局部治疗方案用尽后无转移疾病的生化复发患者以及转移性激素敏感前列腺癌患者的预后和治疗建议。请参阅第二部分，了解去势抵抗性疾病的管理。
为了为该指南提供信息，使用了独立的方法顾问进行系统评价。研究图书馆员在 Ovid MEDLINE（1998 年至 2019 年 1 月第 5 周）、Cochrane 对照试验中心注册（截至 2018 年 12 月）和 Cochrane 系统评价数据库（2005 年至 2019 年 2 月 6 日）中进行了检索。在 2020 年 1 月 20 日之前出版前进行了更新搜索。方法团队通过补充电子数据库搜索，纳入了之前 AUA 审查中的研究，并审查了相关文章的参考文献列表。
高级前列腺癌小组制定了基于证据和共识的指南声明，以帮助临床医生管理晚期前列腺癌患者。这些声明如图 1[图：见正文]所示，并在此详细概述。
本指南旨在提高临床医生治疗诊断为晚期前列腺癌患者的能力。未来试验继续进行研究和发表高质量证据对于改善这些患者的护理水平至关重要。
